Literature DB >> 11704610

The role of immunoglobulin E in allergy and asthma.

T A Platts-Mills1.   

Abstract

It has been nearly a century since the first suggestion that a soluble factor in plasma or serum might be responsible for the symptoms of allergic disease and asthma, and more than 30 yr since immunoglobulin E (IgE) was identified as the key molecule in mediating what are now described as type 1 hypersensitivity reactions (allergic asthma, allergic rhinitis, food allergy, atopic dermatitis, some forms of drug allergy, and insect sting allergy). Since that time, many of the details of the inflammatory cascade underlying allergy and asthma have been elucidated, and IgE is now known to play a key upstream role. The goals of this report are to review the cellular and molecular events set in motion by IgE and to examine the evidence for its participation in both the immediate allergic response and the late-phase or chronic inflammatory response in the skin and lungs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704610     DOI: 10.1164/ajrccm.164.supplement_1.2103024

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  72 in total

1.  Analysis of amino acid sequence variations and immunoglobulin E-binding epitopes of German cockroach tropomyosin.

Authors:  Kyoung Yong Jeong; Jongweon Lee; In-Yong Lee; Han-Il Ree; Chein-Soo Hong; Tai-Soon Yong
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

Review 2.  HIV and asthma, is there an association?

Authors:  Jessica A Kynyk; Jonathan P Parsons; Michael F Para; Susan L Koletar; Philip T Diaz; John G Mastronarde
Journal:  Respir Med       Date:  2012-01-27       Impact factor: 3.415

3.  Combination Therapy with Curcumin Alone Plus Piperine Ameliorates Ovalbumin-Induced Chronic Asthma in Mice.

Authors:  Preeti S Chauhan; Anju Jaiswal; Rashmi Singh
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

Review 4.  Preventing progression of allergic rhinitis to asthma.

Authors:  Jaymin B Morjaria; Massimo Caruso; Emma Rosalia; Cristina Russo; Riccardo Polosa
Journal:  Curr Allergy Asthma Rep       Date:  2014-02       Impact factor: 4.806

5.  B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb.

Authors:  Xinxin Nie; Wenni Chen; Ying Zhu; Baozhu Huang; Weiwei Yu; Zhanshuai Wu; Sizheng Guo; Yiping Zhu; Liqun Luo; Shengdian Wang; Lieping Chen
Journal:  Cell Mol Immunol       Date:  2017-05-08       Impact factor: 11.530

6.  Tetanus vaccination is associated with differential DNA-methylation: Reduces the risk of asthma in adolescence.

Authors:  Vimala Devi Janjanam; Nandini Mukherjee; Gabrielle A Lockett; Faisal I Rezwan; Ramesh Kurukulaaratchy; Frances Mitchell; Hongmei Zhang; Hasan Arshad; John W Holloway; Wilfried Karmaus
Journal:  Vaccine       Date:  2016-11-17       Impact factor: 3.641

7.  From Influenza Virus Infections to Lupus: Synchronous Estrogen Receptor α and RNA Polymerase II Binding Within the Immunoglobulin Heavy Chain Locus.

Authors:  Bart G Jones; Robert E Sealy; Rhiannon R Penkert; Sherri L Surman; Barbara K Birshtein; Beisi Xu; Geoffrey Neale; Robert W Maul; Patricia J Gearhart; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-02-27       Impact factor: 2.257

8.  Needleless intranasal administration of HVJ-E containing allergen attenuates experimental allergic rhinitis.

Authors:  Eri Yasuoka; Kazuo Oshima; Katsuto Tamai; Takeshi Kubo; Yasufumi Kaneda
Journal:  J Mol Med (Berl)       Date:  2006-10-28       Impact factor: 4.599

9.  IgE-dependent enhancement of Th2 cell-mediated allergic inflammation in the airways.

Authors:  Y Maezawa; H Nakajima; Y Seto; A Suto; K Kumano; S Kubo; H Karasuyama; Y Saito; I Iwamoto
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

10.  Oral administration of PPC enhances antigen-specific CD8+ T cell responses while reducing IgE levels in sensitized mice.

Authors:  Mike Burrows; Deepak Assundani; Esteban Celis; Frank Tufaro; Akiko Tanaka; W Guy Bradley
Journal:  BMC Complement Altern Med       Date:  2009-11-30       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.